Free tool
FAERS Monitor: Zydelig
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206545 or its brand name (Zydelig, Idelalisib). Reports on generic versions are filed under their own applications.
Reports
7,040
Serious
6,806
97% of reports
Hospitalization
2,991
Death reported
1,612
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- disease progression1,225
- death802
- diarrhoea771
- off label use573
- pneumonia437
- pyrexia375
- drug ineffective318
- fatigue301
- dehydration244
- neutropenia224
- dyspnoea220
- colitis203
- asthenia202
- pneumonitis200
- rash182
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 4 |
| 2014 | 253 |
| 2015 | 1,404 |
| 2016 | 1,357 |
| 2017 | 1,226 |
| 2018 | 980 |
| 2019 | 586 |
| 2020 | 377 |
| 2021 | 257 |
| 2022 | 197 |
| 2023 | 182 |
| 2024 | 113 |
| 2025 | 94 |
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,119 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| disease progressionSignal | 1,225 | 31.2 | 29.7 | 35,662 |
| pneumonitisSignal | 200 | 22.1 | 19.3 | 3,983 |
| colitisSignal | 203 | 16.1 | 14.0 | 2,845 |
| dehydrationSignal | 244 | 5.5 | 4.8 | 892 |
| neutropeniaSignal | 224 | 4.9 | 4.3 | 701 |
| pneumoniaSignal | 437 | 4.0 | 3.7 | 1,009 |
| diarrhoeaSignal | 771 | 3.6 | 3.3 | 1,468 |
| pyrexiaSignal | 375 | 3.2 | 2.9 | 588 |
| deathSignal | 802 | 2.8 | 2.6 | 952 |
| off label use | 573 | 2.0 | 1.8 | 278 |
| asthenia | 202 | 1.6 | 1.4 | 46 |
| rash | 182 | 1.2 | 1.1 | 9 |
| dyspnoea | 220 | 1.2 | 1.0 | 5 |
| fatigue | 301 | 1.2 | 1.0 | 6 |
| drug ineffective | 318 | 0.7 | 0.6 | 36 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.